Cleo Diagnostics expands ovarian cancer trial

Cleo Diagnostics (ASX:COV) has announced a significant expansion of its clinical trial for an ovarian cancer blood test. The company is partnering with Siles Health, a network of women's health and ultrasound clinics in Melbourne and regional Victoria, to enhance the trial. This move aims to provide additional insights into clinical workflows and increase the patient sample size to support their U.S. FDA-enabling trial.

Overview of Cleo Diagnostics' trial expansion and future goals

Cleo Diagnostics (ASX:COV) is expanding its ovarian cancer blood test trial by partnering with Siles Health. This collaboration aims to enhance the trial by increasing the patient cohort and gathering insights into clinical workflows. The test, based on the CXCL10 biomarker, seeks to improve early detection of ovarian cancer. Cleo's broader strategy includes market adoption and global optimization of the test. The company is focused on transforming diagnostic practices and improving outcomes for women's health.

Insights from key stakeholders on the partnership

Associate Professor Charles Siles expressed enthusiasm for the collaboration, citing shared goals in advancing women's health. CEO Richard Allman emphasized the importance of partnerships in transforming ovarian cancer diagnostics and achieving market adoption, especially in the U.S.